Date: 2017-05-08
Type of information: Nomination
Compound: chief scientific officer
Company: Audentes Therapeutics (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 8, 2017, Audentes Therapeutics announced the appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer. Dr. Gray joined Audentes in 2014 as Vice President, Research and Development, and has successfully built and led teams across the Company's molecular biology, process development, and nonclinical research and development functions.
- Dr. Gray joined Audentes with over 20 years of experience designing genetic therapies and vaccines, and developing manufacturing processes for those products. Immediately prior to Audentes, Dr. Gray served as the Director of Vector Production and Development at St. Jude Children's Research Hospital where he led a team devoted to advancing gene therapy vector science. He was a key contributor to the Hemophilia B gene therapy project, for which he designed the self-complementary AAV Factor IX vector expression cassette and developed the GMP production process used to manufacture the clinical vector. During his tenure at St. Jude, Dr. Gray also worked on Chimeric Antigen Receptor modified cell therapy, lysosomal storage disorder gene therapy, and multiple hematopoietic stem/progenitor cell gene therapy projects utilizing both AAV and lentiviral vectors. Prior to joining St. Jude, Dr. Gray served as the assistant director of the Harvard Gene Therapy Initiative and prior to that, worked at Pfizer Animal Health designing bacterial and viral vectors for vaccine applications. Dr. Gray has a Bachelor of Arts degree in Biochemistry from the University of California, Berkeley, and a Ph.D. degree in Biochemistry from the University of Colorado, Boulder.
Financial terms:
Latest news:
Is general: Yes
